160 related articles for article (PubMed ID: 31480046)
1. Crizotinib-Associated Renal Cysts in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients: A Single-Center Experience.
Eiamprapaporn P; Mungwatthana N; Twinprai P; Sookprasert A; Chindaprasirt J; Ahooja A; Watthanaudomrot S; Sirithanaphol W
Urol Int; 2020; 104(3-4):269-272. PubMed ID: 31480046
[TBL] [Abstract][Full Text] [Related]
2. Complex renal cysts combined with hemorrhage during crizotinib treatment for ALK-rearranged lung adenocarcinoma.
Yang L; Gu J; Niu X
Cancer Treat Res Commun; 2021; 27():100373. PubMed ID: 33865115
[TBL] [Abstract][Full Text] [Related]
3. Renal Injury during Long-Term Crizotinib Therapy.
Yasuma T; Kobayashi T; D'Alessandro-Gabazza CN; Fujimoto H; Ito K; Nishii Y; Nishihama K; Baffour Tonto P; Takeshita A; Toda M; Gabazza EC; Taguchi O; Yonemura S; Hataji O
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257437
[TBL] [Abstract][Full Text] [Related]
4. Development of complex renal cysts: A complication associated with Crizotinib therapy.
Chen F; Patel NJ; Legout JD; Caserta MP
Clin Imaging; 2020 Sep; 65():15-17. PubMed ID: 32353713
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
6. Brigatinib versus crizotinib for ALK-positive NSCLC.
Stirrups R
Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790
[No Abstract] [Full Text] [Related]
7. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
Ock CY; Yoo SH; Keam B; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
Korean J Intern Med; 2019 Sep; 34(5):1116-1124. PubMed ID: 29950554
[TBL] [Abstract][Full Text] [Related]
8. Complex renal cysts associated with crizotinib treatment.
Schnell P; Bartlett CH; Solomon BJ; Tassell V; Shaw AT; de Pas T; Lee SH; Lee GK; Tanaka K; Tan W; Tang Y; Wilner KD; Safferman A; Han JY
Cancer Med; 2015 Jun; 4(6):887-96. PubMed ID: 25756473
[TBL] [Abstract][Full Text] [Related]
9. [Renal cysts - A novel complication of crizotinib treatment for lung cancer].
CsToth I; Meert AP; Sculier JP; Berghmans T
Rev Mal Respir; 2015 Nov; 32(9):956-8. PubMed ID: 26033699
[TBL] [Abstract][Full Text] [Related]
10. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report.
Guisier F; Piton N; Bellefleur M; Delberghe N; Avenel G; Angot E; Vittecoq O; Ould-Slimane M; Morisse-Pradier H; Salaun M; Thiberville L
BMC Cancer; 2020 Jan; 20(1):14. PubMed ID: 31906956
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event.
Adhikari N; Kumar P; Venkatesulu BP; Pandey R; Haresh KP; Gupta S; Sharma DN; Rath GK
J Glob Oncol; 2018 Sep; 4():1-4. PubMed ID: 30241172
[No Abstract] [Full Text] [Related]
13. Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer.
Deng H; Li B; Li L; Peng J; Lv T; Liu Y; Ding C
Pathol Res Pract; 2019 Dec; 215(12):152695. PubMed ID: 31699471
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution.
Cameron LB; Jiang DH; Moodie K; Mitchell C; Solomon B; Parameswaran BK
Cancer Imaging; 2017 Feb; 17(1):7. PubMed ID: 28209203
[TBL] [Abstract][Full Text] [Related]
15. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
[TBL] [Abstract][Full Text] [Related]
16. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
17. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib-associated Renal Cyst Formation in a Pediatric Patient With ALK+ Epithelioid Inflammatory Myofibroblastic Sarcoma.
Kopelevich A; Holzman SA; La J; Lai HA; Torno L; Stephany HA
Urology; 2021 Mar; 149():222-224. PubMed ID: 32882306
[TBL] [Abstract][Full Text] [Related]
19. Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature.
Zhang P; Xu J; Wu Q; Qian J; Wang S
Diagn Pathol; 2024 Apr; 19(1):58. PubMed ID: 38616252
[TBL] [Abstract][Full Text] [Related]
20. Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib.
Taima K; Tanaka H; Tanaka Y; Itoga M; Takanashi S; Tasaka S
Intern Med; 2017 Sep; 56(17):2321-2324. PubMed ID: 28794366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
